News – Page 39 – Global Reach Health

November 15, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/11/Mvasi-Receives-New-Cancer-Indication-480x360.jpg" class="scale-with-grid wp-post-image" alt="Mvasi-Receives-New-Cancer-Indication" decoding="async" />

Mvasi-Receives-New-Cancer-Indication

Mvasi Receives New Cancer Indication

November 15, 2021 – Mvasi^® (bevacizumab-awwb) has received a new indication to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug, manufactured by Amgen

November 15, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/11/Ruxience-Approved-to-Treat-Rheumatoid-Arthritis-480x360.jpg" class="scale-with-grid wp-post-image" alt="Ruxience-Approved-to-Treat-Rheumatoid-Arthritis" decoding="async" />

Ruxience-Approved-to-Treat-Rheumatoid-Arthritis

Ruxience Approved to Treat Rheumatoid Arthritis

November 15, 2021 – The U.S. FDA has approved a new indication for Ruxience^® (rituximab-pvvr), Pfizer's biosimilar for Genentech and Biogen’s Rituxan^® (rituximab)

November 15, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/11/Besremi-Approved-for-Rare-Cancer-480x360.jpg" class="scale-with-grid wp-post-image" alt="Besremi-Approved-for-Rare-Cancer" decoding="async" />

Besremi-Approved-for-Rare-Cancer

Besremi Approved for Rare Cancer

November 15, 2021 – PharmaEssentia's Besremi^® (ropeginterferon alfa-2b-njft) has been approved to treat polycythemia vera (PV) in adults. It is the only interferon drug FDA approved

November 8, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/11/headache-migraine-woman-480x360.jpg" class="scale-with-grid wp-post-image" alt="headache-migraine-woman" decoding="async" />

headache-migraine-woman

Eprontia Approved for Seizures and Migraines

November 8, 2021 – Eprontia^TM (topiramate) 25mg/mL oral solution has received U.S. FDA approval to treat seizures and prevent migraines in children and adults.

November 5, 2021

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/11/Dyanavel-XR-Approved-in-Tablet-Form-480x360.jpg" class="scale-with-grid wp-post-image" alt="Dyanavel-XR-Approved-in-Tablet-Form" decoding="async" />

Dyanavel-XR-Approved-in-Tablet-Form

Dyanavel XR Approved in Tablet Form

November 5, 2021 – A new dosage form of Dyanavel XR^® (amphetamine) has received U.S. FDA approval to treat attention deficit hyperactivity disorder (ADHD) in patients who are at

November 3, 2021

CDC May Expand Hepatitis B Vaccination Recommendations

November 3, 2021 – The Advisory Committee on Immunization Practices (ACIP) for the U.S. Centers for Disease Control and Prevention (CDC) now recommends hepatitis B

November 1, 2021

Purified Cortrophin Gel Approved

November 1, 2021 – ANI Pharmaceuticals has announced U.S. FDA approval of the company’s Purified Cortrophin^TM Gel (repository corticotropin injection). The product is indicated to treat

October 29, 2021

Comirnaty Authorized to Prevent COVID-19 in Children 5-11 Years Old

October 29, 2021 – Comirnaty^® (COVID-19 vaccine, mRNA – Pfizer/BioNTech) has received emergency use authorization (EUA) to prevent COVID-19 in children 5-11 years